Surfactant Protein C Gene (SFPTC) Mutation-Associated Lung Disease: High-Resolution Computed Tomography (HRCT) Findings and its Relation to Histological Analysis: HRCT and histological finding of SFTPC mutations by Mechri, Meriem et al.
Surfactant Protein C Gene (SFPTC)
Mutation-Associated Lung Disease: High-Resolution
Computed Tomography (HRCT) Findings and its
Relation to Histological Analysis
Meriem Mechri, Ralph Epaud, Sophie Emond, Aurore Coulomb, Francis
Jaubert, Delphine Feldmann, Annick Cle´ment, Ailbhe Tarrant, Jacques De
Blic, Rola Abou Taam, et al.
To cite this version:
Meriem Mechri, Ralph Epaud, Sophie Emond, Aurore Coulomb, Francis Jaubert, et al.. Surfac-
tant Protein C Gene (SFPTC) Mutation-Associated Lung Disease: High-Resolution Computed
Tomography (HRCT) Findings and its Relation to Histological Analysis: HRCT and histo-




Submitted on 23 Jan 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de











Surfactant Protein C Gene (SFPTC) Mutation–Associated 
Lung Disease: High-Resolution Computed Tomography 
(HRCT) Findings and its Relation to Histological Analysis 
 
 
Journal: Pediatric Pulmonology 
Manuscript ID: PPUL-10-0006.R2 
Wiley - Manuscript type: Original Article 
Date Submitted by the 
Author: 
12-May-2010 
Complete List of Authors: Mechri, Meriem; Hopital Armand Trousseau, Pediatric Radiology 
department 
epaud, ralph; Hôpital Armand Trousseau, Pediatric Pulmonary 
Department, INSERM UMR-S 938 
emond, sophie; Necker Enfants Malades hospital, pediatric 
pulmonology 
Coulomb, Aurore; Hôpital Armand Trousseau, Histological 
Department 
jaubert, francis; Necker Enfants Malades hospital, laboratoire 
d'anatomopathologie 
feldmann, delphine; armand Trousseau hospital, laboratoire de 
biochimie 
Clément, Annick; AP-HP, Hopital Armand Trousseau, Pediatric 
pulmonology and INSERM UMR S-719 
Tarrant, Ailbhe; Hôpital Armand Trousseau, Pediatric Radiology 
department 
de Blic, Jacques; Necker Enfants Malades, Pneumology 
ABOU TAAM, ROLA; Necker Enfants Malades hospital, pediatric 
pulmonology 
Brunelle, Francis; Hopital Necker Enfants malades, Pediatric 
Radiology Deparment 
Ducou Le pointe, Hubert; Hôpital Armand Trousseau, Pediatric 
Radiology department 








Page 1 of 42
































































Surfactant Protein C Gene (SFTPC) Mutation–Associated Lung Disease: 
High-Resolution Computed Tomography (HRCT) Findings and its Relation 
to Histological Analysis 
M. Mechri*1, 2, 3, R. Epaud*2, 3, 4, 5, S. Emond1, 6, 7, A. Coulomb2, 3, 8, F. Jaubert 1, 6, 8, A. Tarrant1, 2, 3, D. 
Feldmann2, 3, 9, F. Flamein2, 4, A. Clement2, 3, 4, 5J. de Blic5, 6, 7, R. Abou Taam5, 6, 7, F. Brunelle1, 6, 7, H. 
Ducou le Pointe1, 2, 3 
1Pediatric Radiology Department. 2UPMC Univ Paris 06, France; 3AP-HP, Hôpital Armand Trousseau, 
4INSERM UMR_S U938, Paris, France; 5Pediatric Pulmonary Department; 6Université Paris 
Descartes ; 7AP-HP, Hôpital Necker Enfants Malades, Paris, France; 8Histological department, 
9Biochemistry Department.  
*These authors contributed equally to this work and should be considered as first author. 
 
The authors have no conflicts of interest to disclose. 
 
Running title: HRCT and histological finding of SFTPC mutations 
Keywords: surfactant protein C, HRCT, Histological. 
 
Corresponding authors: 
Pr. Hubert Ducou Le pointe 
Pediatric Radiology Department  
Hôpital d'Enfants Armand Trousseau 
26 Avenue du Dr Arnold Netter 
F-75571 Paris cedex 12, France 
Email : hubert.ducou-le-pointe@trs.aphp.fr 
 
Page 2 of 42


































































Aim of the study 
Determine high-resolution tomography (HRCT) scan characteristics in children with SFTPC 
mutation and correlate them to histological findings. 
Patients and Methods 
This retrospective multicenter study included 15 children (7 females and 8 males) with 
SFTPC mutations. HRCT scans have been performed in all the children and lung biopsies in 8 
children. 
 Results  
From all signs assessed on initial HRCT scans, ground-glass opacities (n=14, 93 %) and lung 
cysts (n=6, 40 %) were predominant. Interlobular septal thickening (n=1, 7 %), air space 
consolidation (n=1, 7 %), paraseptal emphysema (n=2, 13 %), and pulmonary nodules (n=1, 7 
%) were also found. Histological analysis revealed accumulation of macrophages in the 
alveolar lumen, type II pneumocyte hyperplasia, and alveolar septal thickening. Dilatation of 
the respiratory bronchiole and alveolar duct associated with muscular hyperplasia were also 
described. Interestingly, lung cysts on HRCT scans were associated with dilatation of terminal 
bronchioli and alveolar duct in lung biopsies. 
Conclusion 
In children with SFTPC mutations, HRCT scan finding were highly correlated to the 
histological findings and, as such, represent a useful tool to identify patients that may require 
SFTPC gene sequencing. 
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Idiopathic forms of interstitial lung disease (ILD) in children are associated with a wide 
spectrum of underlying pathologies. Until recently, a single classification system has been 
used, regardless of age, and children with ILD were forced into published adult disease 
classification systems 1.  In 2007, a multi-disciplinary working group of pediatric pathologists, 
clinicians and radiologist (the Children’s Interstitial Lung Disease (chILD) Research 
Cooperative) designed and conducted a retrospective clinical, radiographic and 
histopathologic review and proposed a new classification system for children with diffuse 
lung disease (chILD syndrome) 2. In this classification, surfactant genetic abnormalities 
account for more than 10 % of the patients reviewed. Pulmonary surfactant is a mixture of 
phospholipids and specific proteins secreted by type II epithelial cell to reduce the alveolar 
surface tension at the air-liquid interface and prevent end-expiratory atelectasis 3. The 
hydrophobic surfactant protein SP-C, play an important role in the spreading and stabilization 
of phospholipids films in the alveolus 3 highlighted by lung disease caused by inherited 
abnormalities in its genes 4,5. Since the first description by Nogee et al., more than 35 
dominantly expressed mutations in the SFTPC gene have been identified in association with 
acute or chronic lung disease in patients ranging in age from newborn to adults 6-10. These 
mutations, whether inherited or spontaneous are always found in an autosomal dominant 
form, the most frequently observed (nearly 50 %) being p.[Ile73Thr] or I73T). The phenotype 
associated with SFTPC mutations is eminently variable. Indeed, neonatal forms leading to 
death in the first years of life as well as childhood and adult forms with chronic respiratory 
disease have been observed. The effects of SFTPC mutations on surfactant homeostasis have 
not been clearly elucidated. In an in vitro study off cells with a SFTPC deletion, accumulation 
of misfolded proSP-C in the Endoplasmic reticulum (ER) causes disruption of the 
ubiquitin/proteasome system 11, activates apoptosis and interferes with non mutated protein 
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synthesis. It results in the release of pro-inflammatory cytokines and enhances T-cell and 
fibroblast recruitment 12.  
Although consensus exists on the need to consider early open lung in children with ILD, 
genetic testing for SFTPC mutation has become widespread and may be performed relatively 
quickly. In addition, recent advances in imaging techniques have contributed to more 
efficiently predict histological findings. Indeed, HRCT has been proposed for either diagnosis 
or following ILD precluding the need to obtain a surgical biopsy 13,14. Thus, the aim of the 
present study was to determine HRCT features of children with SFTPC mutation and to bring 
new insight in the correlation between HRCT and histological findings. To address these 
questions HRCT finding of a cohort of 15 children with interstitial chronic lung disease 
related to SFTPC gene mutations were retrospectively reviewed and subsequently correlated 
with histological analysis when lung biopsies were available.  
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Patients and Methods 
This study is a retrospective study performed in 2 university hospital-based pediatric 
pulmonology practice (Hôpital Armand Trousseau and Hôpital Necker enfants-malades, Paris, 
France) for a 15-year period (1993-2008). The protocol was accepted by the Committee for 
the protection of individuals in Biochemical research as required by French legislation and 




The characteristics of patients are summarized in Table 1. Fifteen children, 7 females 
and 8 males with a definitive diagnosis of SFTPC gene mutation were included. All the 
patients were immunocompetent and screening for metabolic, infectious, and immunological 
etiologies was negative. Genetic and clinical characteristics of all these patients have been 
described in detail in previous reports  8,15. Three patients, members, or relatives of a same 
family, have also been reported previously 6. Median age of onset was 2 (range 0-18) months. 
Three patients had neonatal respiratory distress, and symptom onset was associated with acute 
bronchiolitis in 7 (47 %) patients. Cough, tachypnea, and gastroesophageal reflux and failure 
to thrive were initially noticed in all the children. Physical examination at presentation 
revealed tachypnea and retraction in all patients. Low oxygen saturation (<95%) was observed 
initially in all patients. Treatment are summarized in table 1 and included methylprednisolone 
pulse (n=15), hydroxychloroquin (n=8) and azithromycin (n=5). Median follow-up was 3.1 
(1-17.3) years. At the end of the study, all the children were alive but 11 patients (73 %) were 
still symptomatic with cough, dyspnea or exercise intolerance.  
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HRCT scan and image analysis 
CT examinations were performed with two helical scanners and two multidetector CT 
scanners. In Armand Trousseau hospital, Elscint (CT Twin) with scan acquisition at 120 kV, 
120 mAs and after 2003 a Philips (Mx 8000 IDT32) 16 slice multidetector CT was used with 
scan acquisition at the 90kV, 90mAs. In Necker Hospital, General Electric helical CT 
(Prospeed) with scan acquisition at 140kV, 130mAs, and after 2005 a General Electric 
(LightSpeed) 64 slice multidetector CT was used with scan acquisition at the 100kV, 100mA. 
All the patients underwent non–contrast-enhanced incremental (at intervals of 3 to 10 mm) or 
helical HRCT scan with a collimation of 16 X 1mm. Scans were obtained from the level of 
apices to the diaphragm. Image reconstruction was performed with a high special frequency 
algorithm. All CT scans were performed before the diagnosis, and none of the patients were 
receiving treatment at the time of first HRCT. The HRCT scans (initial and follow-up) were 
reviewed and interpreted by 2 experienced pediatric radiologists who arrived at their 
interpretations by consensus without knowledge of histological parameters. HRCT scan 
analysis was performed with reference to a conventional model in line with Austin’s 
definition 
The scans were assessed for the presence, extent, and distribution of elementary lesions, 
such us areas of ground-glass opacity, lung cysts, lung consolidation, interlobular and 
intralobular septal thickening, thickening of bronchovascular bundles, and nodules 
(centrolobular or other).The anatomical distribution was classified as central (a predominance 
of abnormalities in the inner two-thirds of the lung), peripheral (a predominance of 
abnormalities in the outer one-third of the lung or along the interlobar fissures), or random (no 
central or peripheral predominance). The zonal predominance of abnormalities was assessed 
as being upper, intermediate lower, or random. Upper lung zone predominance was 
considered present when the extent of abnormalities was greatest above the level of the 
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tracheal carina; intermediate was considered between the carina and inferior pulmonary veins, 
and lower zone predominance was considered present when disease extent was greatest below 
this level. Specific involvement or sparing of the subpleural region (<1cm from the pleura) 
was assessed. Ground-glass opacities describe lung that is higher in attenuation than a normal 
lung on inspiration but lower than the attenuation of bronchial walls and blood vessels so that 
these lung markings remain visible 16. The term lung cyst is used to refer to a well-defined, 
rounded, and circumscribed lesion, with a wall that may be uniform or varied in thickness but 
which is usually thin (with thickness of less than 3 mm) 17. Because this study was 
retrospective, the intervals of follow-up HRCT scanners were highly centre-dependent and 
based on the decision of the physician in charge of the child. Only HRCT scanners available 
ware taking into consideration for analysis. Control HRCT scans were obtained from 6 age-
matched patients with a definitive diagnosis of ABCA3 (ATP-binding cassette subfamily A, 
member 3) mutations, a gene expressed in lamellar bodies of alveolar type II cells which has a 
critical role in surfactant storage and homeostasis 18. Among them, 2 patients carried 
homozygous missense mutations, 3 patients carried compound heterozygous missense 
mutations and 1 child had compound heterozygous missense and nonsense mutations.  
Median age at HRCT scans was 2 months (range 1 month to 12 years).  
 
Lung biopsies and their analysis 
Surgical lung biopsies ranging from 0.5 to 1cm were obtained from different lobes in 8 
children at the age of 3 to 7 months (mean age, 4 months) before treatment onset. Biopsy sites 
are summarized in Table 1. Specimens were further fixed in formalin and embedded in 
paraffin. A five-micrometer tissue section was stained with H and E stain (hematoxylin and 
eosin stain). Slides were examined by 2 pathologists. Radiology-pathology correlation was 
performed in 8 cases. All 8 children had only 1 open lung biopsy. 
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 Initial HRCT findings 
The median age at initial HRCT scanner was 4 (range 1-40) months (one child had the 
scanner performed 40 months after the diagnosis for technical reasons). High-resolution CT 
findings are summarized in Table 2. The most frequent abnormalities identified on initial 
HRCT were ground-glass opacities (93 %) and lung cysts (40 %). Other abnormalities noted 
included interlobular septal thickening (7 %), air space consolidation (7 %), paraseptal 
emphysema (13 %), and pulmonary nodules (7 %). In comparison, ground-glass opacities 
were constantly observed in all of the 6 patients with ABCA3 mutations. However, opacities 
were more prominent with presence in some cases of alveolar condensations. 
Bilateral ground-glass opacities were shown in 14 children (Table 3), either as an isolated 
finding (60 %) or as part of a mixed pattern with lung cysts (33 %), air space consolidation (7 
%), paraseptal emphysema, and centrolobular nodules (7 %). They were homogeneously 
diffuse in 9 cases (60 %) (Figure 1A). When a patchy distribution was present, this was noted 
to have basal subpleural predominance in 1 case (7 %), predominance for the lower lobes in 2 
cases (13 %) (Figure 1B), a central predominance in 1 case (7 %), and a predominance for the 
posterior portions of the lung in 1 case (7 %). 
Thin-walled (<1mm) lung cysts of varying sizes were seen in 6 infants (40 %) (Table 4), 
either as an isolated finding (7 %) (Figure 2A), or as a mixed pattern with areas of ground-
glass opacities (33 %), paraseptal emphysema (13 %) (Figure 2B), septal thickening (7 %), 
and non-septal thickening (7 %). A predominantly subpleural distribution was seen in 1 child 
(7 %); diffuse cysts with random distribution was seen in 4 cases (27 %) and upper lung zone 
predominance was seen in 1 case (7 %).  
Follow-up HRCT scan 
Page 9 of 42
































































Follow-up CT scans were performed on 11 of the 15 children. The median follow-up interval 
was 8 (range 3-12) months. Eight patients had 1 follow-up HRCT scan, 2 patients had 2 
follow-up HRCT scans (3 and 9 months and 4 and 9 months, respectively), and 1 patient had 3 
follow-up HRCT scans (3, 6 and 12 months). Evaluation of the follow-up HRCT scans (Table 
5) revealed the development of lung cysts in 5 patients (45 %) who had previously only had 
ground-glass opacities (Figures 3A and 3B). These new cystic changes were associated with a 
stable pattern of ground-glass opacities in 2 cases, decrease in the degree of ground-glass 
opacities in 1 case, and an aggravation of this pattern in 2 cases. These cysts were diffuse in 
all cases but showed a predilection for different regions of the lung: upper lobes (n=1), basal 
subpleural (n=1), peripheral (n=1), and central (n=1). In 1 case, lung cysts were homogenous 
and diffuse. Patients who had previously documented cysts on their initial HRCT scans also 
demonstrated change when follow-up HRCT was performed. In 5 patients (45 %), we noted 
an increase in the number or size of preexisting lung cysts (Figures 4A and 4B), which were 
associated with stable ground-glass opacities (n=4), aggravated ground-glass opacities (n=1), 
and progressive pulmonary fibrosis (n=1). The HRCT findings of pulmonary fibrosis 
consisted of bilateral and diffuse honeycombing, septal and non-septal thickening, and 
thickening of bronchovascular bundles and distortion of pulmonary fissures. In 1 patient, we 
observed persistent isolated ground-glass opacities. 
Pathology findings 
Eight of the 15 patients (53 %) underwent lung biopsy the median age at biopsy being 4 
(range 3-7) months. Histological analysis revealed 2 main types of lesions. The first type 
occurred in the alveolar lumen, were we observed the following changes: accumulation of 
macrophages intermingled with few inflammatory cells and cholesterol cleft, type II 
pneumocyte hyperplasia, and alveolar septal thickening by primitive mesenchymal cells and 
lymphocytes either isolated or clustered (Figure 5A). These lesions were diffuse in 7 cases (90 
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%) and patchy in 1 case (13 %). The second type of lesion corresponds to dilatation of the 
respiratory bronchiole and alveolar duct in 7 cases (88 %) associated with muscular 
hyperplasia in 2 patients (25%) (Figure 6A). There was no interstitial pulmonary fibrosis or 
alveolar proteinosis observed. 
 
Relation between HRCT and pathology findings 
Radiological-pathological confrontation is summarized in Table 6. Ground-glass opacities on 
HRCT were observed in all the patients except 1 in which the CT scan was performed late (40 
months). All these children also have diffuse alveolar septal thickening by primitive 
mesenchymal cells and lymphocytes, intra-alveolar accumulation of macrophages, and type II 
pneumocyte hyperplasia. Small lung cysts were observed initially in half of the children but 
appeared during follow-up in all the cases. They were related with dilatation of the terminal 
bronchioles and alveolar duct which were noticed in all but one biopsy. 
 
Discussion:  
In the present study, we have shown for the first time in a large cohort of children with 
SFTPC mutation associated lung diseases that HRCT pattern were characterized with 2 main 
abnormalities: ground-glass opacities that were predominately diffuse but can be patchy in 
some cases and lung cysts with thin wall and different sizes.  
Ground-glass opacities have been commonly described in previous reports 6,19,20. They are 
predominately diffuse but can be patchy in some cases. In our series, they were present in all 
the patients except one in whom the HRCT scan was done late.  We also note in our study the 
high frequency of cystic lesions on HRCT scan. They appeared in 45% of the children during 
follow-up and increased in number in 45%. Similar change during follow-up is typical of 
surfactant abnormality and was noted by Brody16. In our series, ground-glass attenuation 
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decreased in intensity with age, whereas small lung cysts usually became more prominent 
over time. 
This HRCT presentation, namely the ground-glass opacities and cystic patterns is, 
nonetheless, not specific of SFTPC associated disorders. We have shown that this presentation 
may also be observed in children with ABCA3 mutations as previously described 21.However, 
the high frequency of SFTPC associated disorders in children ILD 2,7, the feasibility of SFTPC 
genetic analysis as well as the difficulty to perform lung biopsy in patients with fragile 
respiratory condition strongly encourage to perform SFTPC genetic screening before lung 
biopsy in children with ground-glass opacities associated with cystic lung changes on HRCT 
scanner.  
In the literature, there are histological studies of patients with SFTPC gene mutations showing 
4 histological patterns: desquamative interstitial pneumonitis (DIP), nonspecific interstitial 
pneumonitis(NSIP), (UIP) and pulmonary alveolar proteinosis 7,16,22 in children and usual 
interstitial pneumonitis (UIP) in adults. In children, DIP and NSIP have also been described in 
patients with mutations in the ATP-binding cassette transporter A3 (ABCA3) gene 21. Chibbar 
et al. showed that both children and adults with NSIP and UIP patterns, respectively, carried a 
common mutation within the SFTPC gene 23. Thomas et al. described a mutation in SFTPC 
gene associated with large kindred with familial form of pulmonary fibrosis, including adults 
with the most common pathological subset of pulmonary fibrosis, UIP, and children with 
cellular NSIP 24. Brasch reported histological patterns of NSIP and pulmonary alveolar 
proteinosis in a 13-month-old infant with a de novo heterozygous missense mutation of the 
SFTPC gene 20. The histological findings were classified as DIP because of an increased 
number of macrophages in the alveolar lumen 25 and as NSIP and UIP because of the 
numerous inflammatory cells in the alveolar septum 26,27. In this study, we have related 
ground-glass opacities on HRCT to diffuse alveolar septal thickening by primitive 
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mesenchymal cells and lymphocytes, intra-alveolar accumulation of macrophages, and type II 
pneumocytes hyperplasia. Small lung cysts were related to dilatation of the respiratory 
bronchioli and alveolar duct. On initial HRCT scan analysis, large cystic lung changes in the 
periseptal and subpleural regions were that of subpleural emphysema. On lung biopsies, 
millimetric small cysts corresponding to a dilatation of respiratory bronchioli and alveolar 
ducts, sometimes in subpleural area and periseptal regions, were observed, whereas 
histological emphysema was not present. Large cyst (>1mm) probably corresponds to 
emphysema, whereas small cyst may be in part due to cystic dilatation of the proximal part of 
the acini.  
After natural exposure, CT scan is the greatest contributor to total radiation exposure and 
Brenner et al. notes that the evidence is "convincing" that the radiation dose from CT scans 
can lead to cancer induction in adults and "very convincing" in the case of children 28. Hence, 
it is of importance to adjust protocols in order to reduce unnecessary radiation exposure from 
CT. Exposure parameters have considerably decreased during the study, but these efforts must 
be sustained. In this context, we also recommend to use a sequential technique during follow-
up, including for multi detector CT. 
With this report as our basis, the presence of bilateral ground-glass opacity or a combination 
of ground-glass opacities and cysts suggests the diagnosis of SFTPC mutation associated 
disorders and strongly encourage to perform genetic screening. We believe that this study is of 
value in highlighting this rare condition, and future prospective studies in children and adults 
are needed to further characterize CT findings in surfactant dysfunction disorders. 
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Fig. 1: Four-year-old boy with SFTPC mutation. HRCT section through the carina shows 
diffuse and uniform ground-glass opacities (A).Two-year-old girl with SFTPC mutation. 
Initial HRCT (at 3 months) shows homogenous ground-glass opacity in the lower lobes (B). 
One month old girl with compound heterozygous missense ABCA3 mutations. Initial HRCT 
shows ground-glass opacity in the lower lobes (C). 
 
Fig. 2: Two-year-old girl with SFTPC mutation. Initial HRCT (at 16 months) shows 
paraseptal emphysema (curved arrow) associated with widespread cystic airspaces and diffuse 
ground-glass opacities (A). Seventeen-year-old boy with SFTPC mutation. The HRCT done at 
14 -year -old showed isolated lung cysts with thin wall and variable sizes (B). One month old 
girl with compound heterozygous missense ABCA3 mutations. Initial HRCT shows 
association of ground-glass opacity, alveolar condensations and lung cysts (C). 
 
 
Fig. 3: A one-year-old boy with SFTPC mutation. The initial computed tomography shows 
diffuse ground-glass opacities (A). The follow-up HRCT scan done 14 months later revealed 
the appearance of new lung cysts in lower lobes surimposed on diffuse ground-glass opacities 
(B). 
 
Fig. 4: Two-year-old girl with SFTPC mutation. Initial HRCT scan diffuse shows lung cysts 
with subpleural predominance associated with diffuse ground-glass opacities (A). The follow-
up HRCT scan done 6 months later, revealed an increase in the number and size of lung cysts 
associated with stable ground-glass opacities (B). 
 
Fig. 5: A one-year old boy with SFTPC mutation who underwent lung biopsy in the middle 
lobe. High-power photomicrograph (original magnification × 200, hematoxylin eosine [H- E] 
stain) (A) shows numerous macrophages in alveoli (M) and type II pneumocytes hyperplasia 
(straight arrows) with septal thickening. HRCT section through the middle lobe (B) shows 
diffuse ground glass opacity. 
 
Fig. 6: A 3-year old girl with SFTPC mutation who underwent lung biopsy in the right upper 
lobe. High- power photomicrograph (original magnification × 200, hematoxylin eosine [H- E] 
stain) (A) shows cystic distension of respiratory ducts (curved arrow), numerous macrophages 
in alveoli (M) and type II pneumocytes hyperplasia (straight arrows). HRCT section through 
the upper lobes (B) shows diffuse lung cysts associated with diffuse ground glass opacities. 
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 Table 1: Characteristics of patients 
 
Biopsy: LIL, left inferior lobe; LSL, left superior lobe;  RIL, Right inferior lobe; RML, right medium lobe; RSL, right superior lobe. 
Treatment: MPP, methylprednisolone pulse; H, hydroxychloroquin; A, azithromycin. Oxygen status: OW, oxygen weaning; SOO, still on 







Age at onset 
(months) 
Mutation (protein 
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Table 2: Initial HRCT signs of patients with SFTPC gene mutation 
 
Percentage of total is indicated in parentheses. 
 
 













Lung cysts 6 (40) 3 (50) 
Interlobular septal thickening 1 (7) 2 (30) 
Consolidation  1 (7) 2 (30) 
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Peripheral 1 (7) 1 (13) 
Central  1 (7) 0 (0) 
Posterior 1 (7) 0 (0) 
Lower 2 (13) 1 (13) 
Percentage of total is indicated in parentheses. 
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Subpleural predominance 1 (7) 0 (0) 
Percentage of total is indicated in parentheses. 
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Table 5: Findings on follow-up HRCT scans in patients with SFTPC gene mutation. 
  
















Appeared 5 (45) Lung cyst 
    n = 10 




Percentage of total is indicated in parentheses. 
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of the respiratory 
bronchioli 
Cystic dilatation 
of the alveolar 
duct 
Muscle hyperplasia of the 
respiratory bronchioli 
Increased number of 




Ground-glass opacities Lung cysts 
 
       Initial Follow-up  Initial Follow-up 
1 4 5  + + - + + + - + + 
2 7 8  + + - + + + - + + 
3 6 40 - - - + + - + + + 
4 4 2  + + - + + + + - + 
5 4 6  + + - + + + + + + 
6 4 1  + + + + + + - - + 
7 6 3  + + + + + + + - + 
8 3 2  + + - + + + - - + 
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Fig. 1: Four-year-old boy with SFTPC mutation. HRCT section through the carina shows diffuse and 
uniform ground-glass opacities (A).Two-year-old girl with SFTPC mutation. Initial HRCT (at 3 
months) shows homogenous ground-glass opacity in the lower lobes (B). One month old girl with 
compound heterozygous missense ABCA3 mutations. Initial HRCT shows ground-glass opacity in the 
lower lobes (C).  
190x254mm (96 x 96 DPI)  
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Fig. 2: Two-year-old girl with SFTPC mutation. Initial HRCT (at 16 months) shows paraseptal 
emphysema (curved arrow) associated with widespread cystic airspaces and diffuse ground-glass 
opacities (A). Seventeen-year-old boy with SFTPC mutation. The HRCT done at 14 -year -old 
showed isolated lung cysts with thin wall and variable sizes (B). One month old girl with compound 
heterozygous missense ABCA3 mutations. Initial HRCT shows association of ground-glass opacity, 
alveolar condensations and lung cysts (C).  
190x254mm (96 x 96 DPI)  
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A one-year-old boy with SFTPC gene mutation. The initial computed tomography shows diffuse 
ground-glass opacities (A). The follow-up HRCT scan done 14 months later revealed the appearance 
of new lung cysts in lower lobes surimposed on diffuse ground-glass opacities (B).  
190x254mm (96 x 96 DPI)  
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Fig. 4: Two-year-old girl with SFTPC gene mutation. Initial HRCT scan diffuse shows lung cysts with 
subpleural predominance associated with diffuse ground-glass opacities (A). The follow-up HRCT 
scan done 6 months later, revealed an increase in the number and size of lung cysts associated with 
stable ground-glass opacities (B).  
190x254mm (96 x 96 DPI)  
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A one-year old boy with SFTPC gene mutation who underwent lung biopsy in the middle lobe. High-
power photomicrograph (original magnification × 200, hematoxylin eosine [H- E] stain) (A) shows 
numerous macrophages in alveoli (M) and type II pneumocytes hyperplasia (straight arrows) with 
septal thickening. HRCT section through the middle lobe (B) shows diffuse ground glass opacity.  
190x254mm (96 x 96 DPI)  
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A 3-year old girl with SFTPC gene mutation who underwent lung biopsy in the right upper lobe. 
High- power photomicrograph (original magnification × 200, hematoxylin eosine [H- E] stain) (A) 
shows cystic distension of respiratory ducts (curved arrow), numerous macrophages in alveoli (M) 
and type II pneumocytes hyperplasia (straight arrows). HRCT section through the upper lobes (B) 
shows diffuse lung cysts associated with diffuse ground glass opacities.  
190x254mm (96 x 96 DPI)  
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Aim of the study 
Determine high-resolution tomography (HRCT) scan characteristics in children with SFTPC 
mutation and correlate them to histological findings. 
Patients and Methods 
This retrospective multicenter study included 15 children (7 females and 8 males) with 
SFTPC mutations. HRCT scans have been performed in all the children and lung biopsies in 8 
children. 
 Results  
From all signs assessed on initial HRCT scans, ground-glass opacities (n=14, 93 %) and lung 
cysts (n=6, 40 %) were predominant. Interlobular septal thickening (n=1, 7 %), air space 
consolidation (n=1, 7 %), paraseptal emphysema (n=2, 13 %), and pulmonary nodules (n=1, 7 
%) were also found. Histological analysis revealed accumulation of macrophages in the 
alveolar lumen, type II pneumocyte hyperplasia, and alveolar septal thickening. Dilatation of 
the respiratory bronchiole and alveolar duct associated with muscular hyperplasia were also 
described. Interestingly, lung cysts on HRCT scans were associated with dilatation of terminal 
bronchioli and alveolar duct in lung biopsies. 
Conclusion 
In children with SFTPC mutations, HRCT scan finding were highly correlated to the 
histological findings and, as such, represent a useful tool to identify patients that may require 
SFTPC gene sequencing. 
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Idiopathic forms of interstitial lung disease (ILD) in children are associated with a wide 
spectrum of underlying pathologies. Until recently, a single classification system has been 
used, regardless of age, and children with ILD were forced into published adult disease 
classification systems 1.  In 2007, a multi-disciplinary working group of pediatric pathologists, 
clinicians and radiologist (the Children’s Interstitial Lung Disease (chILD) Research 
Cooperative) designed and conducted a retrospective clinical, radiographic and 
histopathologic review and proposed a new classification system for children with diffuse 
lung disease (chILD syndrome) 2. In this classification, surfactant genetic abnormalities 
account for more than 10 % of the patients reviewed. Pulmonary surfactant is a mixture of 
phospholipids and specific proteins secreted by type II epithelial cell to reduce the alveolar 
surface tension at the air-liquid interface and prevent end-expiratory atelectasis 3. The 
hydrophobic surfactant protein SP-C, play an important role in the spreading and stabilization 
of phospholipids films in the alveolus 3 highlighted by lung disease caused by inherited 
abnormalities in its genes 4,5. Since the first description by Nogee et al., more than 35 
dominantly expressed mutations in the SFTPC gene have been identified in association with 
acute or chronic lung disease in patients ranging in age from newborn to adults 6-10. These 
mutations, whether inherited or spontaneous are always found in an autosomal dominant 
form, the most frequently observed (nearly 50 %) being p.[Ile73Thr] or I73T). The phenotype 
associated with SFTPC mutations is eminently variable. Indeed, neonatal forms leading to 
death in the first years of life as well as childhood and adult forms with chronic respiratory 
disease have been observed. The effects of SFTPC mutations on surfactant homeostasis have 
not been clearly elucidated. In an in vitro study off cells with a SFTPC deletion, accumulation 
of misfolded proSP-C in the Endoplasmic reticulum (ER) causes disruption of the 
ubiquitin/proteasome system 11, activates apoptosis and interferes with non mutated protein 
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synthesis. It results in the release of pro-inflammatory cytokines and enhances T-cell and 
fibroblast recruitment 12.  
Although consensus exists on the need to consider early open lung in children with ILD, 
genetic testing for SFTPC mutation has become widespread and may be performed relatively 
quickly. In addition, recent advances in imaging techniques have contributed to more 
efficiently predict histological findings. Indeed, HRCT has been proposed for either diagnosis 
or following ILD precluding the need to obtain a surgical biopsy 13,14. Thus, the aim of the 
present study was to determine HRCT features of children with SFTPC mutation and to bring 
new insight in the correlation between HRCT and histological findings. To address these 
questions HRCT finding of a cohort of 15 children with interstitial chronic lung disease 
related to SFTPC gene mutations were retrospectively reviewed and subsequently correlated 
with histological analysis when lung biopsies were available.  
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Patients and Methods 
This study is a retrospective study performed in 2 university hospital-based pediatric 
pulmonology practice (Hôpital Armand Trousseau and Hôpital Necker enfants-malades, Paris, 
France) for a 15-year period (1993-2008). The protocol was accepted by the Committee for 
the protection of individuals in Biochemical research as required by French legislation and 




The characteristics of patients are summarized in Table 1. Fifteen children, 7 females 
and 8 males with a definitive diagnosis of SFTPC gene mutation were included. All the 
patients were immunocompetent and screening for metabolic, infectious, and immunological 
etiologies was negative. Genetic and clinical characteristics of all these patients have been 
described in detail in previous reports  8,15. Three patients, members, or relatives of a same 
family, have also been reported previously 6. Median age of onset was 2 (range 0-18) months. 
Three patients had neonatal respiratory distress, and symptom onset was associated with acute 
bronchiolitis in 7 (47 %) patients. Cough, tachypnea, and gastroesophageal reflux and failure 
to thrive were initially noticed in all the children. Physical examination at presentation 
revealed tachypnea and retraction in all patients. Low oxygen saturation (<95%) was observed 
initially in all patients. Treatment are summarized in table 1 and included methylprednisolone 
pulse (n=15), hydroxychloroquin (n=8) and azithromycin (n=5). Median follow-up was 3.1 
(1-17.3) years. At the end of the study, all the children were alive but 11 patients (73 %) were 
still symptomatic with cough, dyspnea or exercise intolerance.  
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HRCT scan and image analysis 
CT examinations were performed with two helical scanners and two multidetector CT 
scanners. In Armand Trousseau hospital, Elscint (CT Twin) with scan acquisition at 120 kV, 
120 mAs and after 2003 a Philips (Mx 8000 IDT32) 16 slice multidetector CT was used with 
scan acquisition at the 90kV, 90mAs. In Necker Hospital, General Electric helical CT 
(Prospeed) with scan acquisition at 140kV, 130mAs, and after 2005 a General Electric 
(LightSpeed) 64 slice multidetector CT was used with scan acquisition at the 100kV, 100mA. 
All the patients underwent non–contrast-enhanced incremental (at intervals of 3 to 10 mm) or 
helical HRCT scan with a collimation of 16 X 1mm. Scans were obtained from the level of 
apices to the diaphragm. Image reconstruction was performed with a high special frequency 
algorithm. All CT scans were performed before the diagnosis, and none of the patients were 
receiving treatment at the time of first HRCT. The HRCT scans (initial and follow-up) were 
reviewed and interpreted by 2 experienced pediatric radiologists who arrived at their 
interpretations by consensus without knowledge of histological parameters. HRCT scan 
analysis was performed with reference to a conventional model in line with Austin’s 
definition 
The scans were assessed for the presence, extent, and distribution of elementary lesions, 
such us areas of ground-glass opacity, lung cysts, lung consolidation, interlobular and 
intralobular septal thickening, thickening of bronchovascular bundles, and nodules 
(centrolobular or other).The anatomical distribution was classified as central (a predominance 
of abnormalities in the inner two-thirds of the lung), peripheral (a predominance of 
abnormalities in the outer one-third of the lung or along the interlobar fissures), or random (no 
central or peripheral predominance). The zonal predominance of abnormalities was assessed 
as being upper, intermediate lower, or random. Upper lung zone predominance was 
considered present when the extent of abnormalities was greatest above the level of the 
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tracheal carina; intermediate was considered between the carina and inferior pulmonary veins, 
and lower zone predominance was considered present when disease extent was greatest below 
this level. Specific involvement or sparing of the subpleural region (<1cm from the pleura) 
was assessed. Ground-glass opacities describe lung that is higher in attenuation than a normal 
lung on inspiration but lower than the attenuation of bronchial walls and blood vessels so that 
these lung markings remain visible 16. The term lung cyst is used to refer to a well-defined, 
rounded, and circumscribed lesion, with a wall that may be uniform or varied in thickness but 
which is usually thin (with thickness of less than 3 mm) 17. Because this study was 
retrospective, the intervals of follow-up HRCT scanners were highly centre-dependent and 
based on the decision of the physician in charge of the child. Only HRCT scanners available 
ware taking into consideration for analysis. Control HRCT scans were obtained from 6 age-
matched patients with a definitive diagnosis of ABCA3 (ATP-binding cassette subfamily A, 
member 3) mutations, a gene expressed in lamellar bodies of alveolar type II cells which has a 
critical role in surfactant storage and homeostasis 18. Among them, 2 patients carried 
homozygous missense mutations, 3 patients carried compound heterozygous missense 
mutations and 1 child had compound heterozygous missense and nonsense mutations.  
Median age at HRCT scans was 2 months (range 1 month to 12 years).  
 
Lung biopsies and their analysis 
Surgical lung biopsies ranging from 0.5 to 1cm were obtained from different lobes in 8 
children at the age of 3 to 7 months (mean age, 4 months) before treatment onset. Biopsy sites 
are summarized in Table 1. Specimens were further fixed in formalin and embedded in 
paraffin. A five-micrometer tissue section was stained with H and E stain (hematoxylin and 
eosin stain). Slides were examined by 2 pathologists. Radiology-pathology correlation was 
performed in 8 cases. All 8 children had only 1 open lung biopsy. 
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 Initial HRCT findings 
The median age at initial HRCT scanner was 4 (range 1-40) months (one child had the 
scanner performed 40 months after the diagnosis for technical reasons). High-resolution CT 
findings are summarized in Table 2. The most frequent abnormalities identified on initial 
HRCT were ground-glass opacities (93 %) and lung cysts (40 %). Other abnormalities noted 
included interlobular septal thickening (7 %), air space consolidation (7 %), paraseptal 
emphysema (13 %), and pulmonary nodules (7 %). In comparison, ground-glass opacities 
were constantly observed in all of the 6 patients with ABCA3 mutations. However, opacities 
were more prominent with presence in some cases of alveolar condensations. 
Bilateral ground-glass opacities were shown in 14 children (Table 3), either as an isolated 
finding (60 %) or as part of a mixed pattern with lung cysts (33 %), air space consolidation (7 
%), paraseptal emphysema, and centrolobular nodules (7 %). They were homogeneously 
diffuse in 9 cases (60 %) (Figure 1A). When a patchy distribution was present, this was noted 
to have basal subpleural predominance in 1 case (7 %), predominance for the lower lobes in 2 
cases (13 %) (Figure 1B), a central predominance in 1 case (7 %), and a predominance for the 
posterior portions of the lung in 1 case (7 %). 
Thin-walled (<1mm) lung cysts of varying sizes were seen in 6 infants (40 %) (Table 4), 
either as an isolated finding (7 %) (Figure 2A), or as a mixed pattern with areas of ground-
glass opacities (33 %), paraseptal emphysema (13 %) (Figure 2B), septal thickening (7 %), 
and non-septal thickening (7 %). A predominantly subpleural distribution was seen in 1 child 
(7 %); diffuse cysts with random distribution was seen in 4 cases (27 %) and upper lung zone 
predominance was seen in 1 case (7 %).  
Follow-up HRCT scan 
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Follow-up CT scans were performed on 11 of the 15 children. The median follow-up interval 
was 8 (range 3-12) months. Eight patients had 1 follow-up HRCT scan, 2 patients had 2 
follow-up HRCT scans (3 and 9 months and 4 and 9 months, respectively), and 1 patient had 3 
follow-up HRCT scans (3, 6 and 12 months). Evaluation of the follow-up HRCT scans (Table 
5) revealed the development of lung cysts in 5 patients (45 %) who had previously only had 
ground-glass opacities (Figures 3A and 3B). These new cystic changes were associated with a 
stable pattern of ground-glass opacities in 2 cases, decrease in the degree of ground-glass 
opacities in 1 case, and an aggravation of this pattern in 2 cases. These cysts were diffuse in 
all cases but showed a predilection for different regions of the lung: upper lobes (n=1), basal 
subpleural (n=1), peripheral (n=1), and central (n=1). In 1 case, lung cysts were homogenous 
and diffuse. Patients who had previously documented cysts on their initial HRCT scans also 
demonstrated change when follow-up HRCT was performed. In 5 patients (45 %), we noted 
an increase in the number or size of preexisting lung cysts (Figures 4A and 4B), which were 
associated with stable ground-glass opacities (n=4), aggravated ground-glass opacities (n=1), 
and progressive pulmonary fibrosis (n=1). The HRCT findings of pulmonary fibrosis 
consisted of bilateral and diffuse honeycombing, septal and non-septal thickening, and 
thickening of bronchovascular bundles and distortion of pulmonary fissures. In 1 patient, we 
observed persistent isolated ground-glass opacities. 
Pathology findings 
Eight of the 15 patients (53 %) underwent lung biopsy the median age at biopsy being 4 
(range 3-7) months. Histological analysis revealed 2 main types of lesions. The first type 
occurred in the alveolar lumen, were we observed the following changes: accumulation of 
macrophages intermingled with few inflammatory cells and cholesterol cleft, type II 
pneumocyte hyperplasia, and alveolar septal thickening by primitive mesenchymal cells and 
lymphocytes either isolated or clustered (Figure 5A). These lesions were diffuse in 7 cases (90 
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%) and patchy in 1 case (13 %). The second type of lesion corresponds to dilatation of the 
respiratory bronchiole and alveolar duct in 7 cases (88 %) associated with muscular 
hyperplasia in 2 patients (25%) (Figure 6A). There was no interstitial pulmonary fibrosis or 
alveolar proteinosis observed. 
 
Relation between HRCT and pathology findings 
Radiological-pathological confrontation is summarized in Table 6. Ground-glass opacities on 
HRCT were observed in all the patients except 1 in which the CT scan was performed late (40 
months). All these children also have diffuse alveolar septal thickening by primitive 
mesenchymal cells and lymphocytes, intra-alveolar accumulation of macrophages, and type II 
pneumocyte hyperplasia. Small lung cysts were observed initially in half of the children but 
appeared during follow-up in all the cases. They were related with dilatation of the terminal 
bronchioles and alveolar duct which were noticed in all but one biopsy. 
 
Discussion:  
In the present study, we have shown for the first time in a large cohort of children with 
SFTPC mutation associated lung diseases that HRCT pattern were characterized with 2 main 
abnormalities: ground-glass opacities that were predominately diffuse but can be patchy in 
some cases and lung cysts with thin wall and different sizes.  
Ground-glass opacities have been commonly described in previous reports 6,19,20. They are 
predominately diffuse but can be patchy in some cases. In our series, they were present in all 
the patients except one in whom the HRCT scan was done late.  We also note in our study the 
high frequency of cystic lesions on HRCT scan. They appeared in 45% of the children during 
follow-up and increased in number in 45%. Similar change during follow-up is typical of 
surfactant abnormality and was noted by Brody16. In our series, ground-glass attenuation 
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decreased in intensity with age, whereas small lung cysts usually became more prominent 
over time. 
This HRCT presentation, namely the ground-glass opacities and cystic patterns is, 
nonetheless, not specific of SFTPC associated disorders. We have shown that this presentation 
may also be observed in children with ABCA3 mutations as previously described 21.However, 
the high frequency of SFTPC associated disorders in children ILD 2,7, the feasibility of SFTPC 
genetic analysis as well as the difficulty to perform lung biopsy in patients with fragile 
respiratory condition strongly encourage to perform SFTPC genetic screening before lung 
biopsy in children with ground-glass opacities associated with cystic lung changes on HRCT 
scanner.  
In the literature, there are histological studies of patients with SFTPC gene mutations showing 
4 histological patterns: desquamative interstitial pneumonitis (DIP), nonspecific interstitial 
pneumonitis(NSIP), (UIP) and pulmonary alveolar proteinosis 7,16,22 in children and usual 
interstitial pneumonitis (UIP) in adults. In children, DIP and NSIP have also been described in 
patients with mutations in the ATP-binding cassette transporter A3 (ABCA3) gene 21. Chibbar 
et al. showed that both children and adults with NSIP and UIP patterns, respectively, carried a 
common mutation within the SFTPC gene 23. Thomas et al. described a mutation in SFTPC 
gene associated with large kindred with familial form of pulmonary fibrosis, including adults 
with the most common pathological subset of pulmonary fibrosis, UIP, and children with 
cellular NSIP 24. Brasch reported histological patterns of NSIP and pulmonary alveolar 
proteinosis in a 13-month-old infant with a de novo heterozygous missense mutation of the 
SFTPC gene 20. The histological findings were classified as DIP because of an increased 
number of macrophages in the alveolar lumen 25 and as NSIP and UIP because of the 
numerous inflammatory cells in the alveolar septum 26,27. In this study, we have related 
ground-glass opacities on HRCT to diffuse alveolar septal thickening by primitive 
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mesenchymal cells and lymphocytes, intra-alveolar accumulation of macrophages, and type II 
pneumocytes hyperplasia. Small lung cysts were related to dilatation of the respiratory 
bronchioli and alveolar duct. On initial HRCT scan analysis, large cystic lung changes in the 
periseptal and subpleural regions were that of subpleural emphysema. On lung biopsies, 
millimetric small cysts corresponding to a dilatation of respiratory bronchioli and alveolar 
ducts, sometimes in subpleural area and periseptal regions, were observed, whereas 
histological emphysema was not present. Large cyst (>1mm) probably corresponds to 
emphysema, whereas small cyst may be in part due to cystic dilatation of the proximal part of 
the acini.  
After natural exposure, CT scan is the greatest contributor to total radiation exposure and 
Brenner et al. notes that the evidence is "convincing" that the radiation dose from CT scans 
can lead to cancer induction in adults and "very convincing" in the case of children 28. Hence, 
it is of importance to adjust protocols in order to reduce unnecessary radiation exposure from 
CT. Exposure parameters have considerably decreased during the study, but these efforts must 
be sustained. In this context, we also recommend to use a sequential technique during follow-
up, including for multi detector CT. 
With this report as our basis, the presence of bilateral ground-glass opacity or a combination 
of ground-glass opacities and cysts suggests the diagnosis of SFTPC mutation associated 
disorders and strongly encourage to perform genetic screening. We believe that this study is of 
value in highlighting this rare condition, and future prospective studies in children and adults 
are needed to further characterize CT findings in surfactant dysfunction disorders. 
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Fig. 1: Four-year-old boy with SFTPC mutation. HRCT section through the carina shows 
diffuse and uniform ground-glass opacities (A).Two-year-old girl with SFTPC mutation. 
Initial HRCT (at 3 months) shows homogenous ground-glass opacity in the lower lobes (B). 
One month old girl with compound heterozygous missense ABCA3 mutations. Initial HRCT 
shows ground-glass opacity in the lower lobes (C). 
 
Fig. 2: Two-year-old girl with SFTPC mutation. Initial HRCT (at 16 months) shows 
paraseptal emphysema (curved arrow) associated with widespread cystic airspaces and diffuse 
ground-glass opacities (A). Seventeen-year-old boy with SFTPC mutation. The HRCT done at 
14 -year -old showed isolated lung cysts with thin wall and variable sizes (B). One month old 
girl with compound heterozygous missense ABCA3 mutations. Initial HRCT shows 
association of ground-glass opacity, alveolar condensations and lung cysts (C). 
 
 
Fig. 3: A one-year-old boy with SFTPC mutation. The initial computed tomography shows 
diffuse ground-glass opacities (A). The follow-up HRCT scan done 14 months later revealed 
the appearance of new lung cysts in lower lobes surimposed on diffuse ground-glass opacities 
(B). 
 
Fig. 4: Two-year-old girl with SFTPC mutation. Initial HRCT scan diffuse shows lung cysts 
with subpleural predominance associated with diffuse ground-glass opacities (A). The follow-
up HRCT scan done 6 months later, revealed an increase in the number and size of lung cysts 
associated with stable ground-glass opacities (B). 
 
Fig. 5: A one-year old boy with SFTPC mutation who underwent lung biopsy in the middle 
lobe. High-power photomicrograph (original magnification × 200, hematoxylin eosine [H- E] 
stain) (A) shows numerous macrophages in alveoli (M) and type II pneumocytes hyperplasia 
(straight arrows) with septal thickening. HRCT section through the middle lobe (B) shows 
diffuse ground glass opacity. 
 
Fig. 6: A 3-year old girl with SFTPC mutation who underwent lung biopsy in the right upper 
lobe. High- power photomicrograph (original magnification × 200, hematoxylin eosine [H- E] 
stain) (A) shows cystic distension of respiratory ducts (curved arrow), numerous macrophages 
in alveoli (M) and type II pneumocytes hyperplasia (straight arrows). HRCT section through 
the upper lobes (B) shows diffuse lung cysts associated with diffuse ground glass opacities. 
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